

I claim:

1. An axon growth stimulation kit comprising
5 a first container means for containing a flowable carrier component or two or more separate components capable once intermingled of forming a flowable carrier component, said flowable carrier components each being capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site and
a second container means for containing a therapeutically active agent for facilitating axon
10 growth at the lesion site
wherein said therapeutically active agent is releasable from said in vivo matrix into the adjacent external environment.
2. An axon growth stimulation kit as defined in claim 1 comprising means for
15 dispersing the therapeutically active agent in said flowable carrier component so as to form a flowable axon growth stimulation composition
and
means for delivering the flowable axon growth stimulation composition to the lesion site.
- 20 3. An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a collagen matrix.
4. An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a fibrin matrix.
- 25 5. A biocompatible composition comprising: (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth; and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the
30 adjacent external environment.

6. A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a collagen matrix.

7. A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a fibrin matrix.

8. A method for the preparation of a flowable biocompatible composition comprising admixing (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

9. A method as defined in claim 8 wherein said therapeutically acceptable matrix is a collagen matrix.

10. A method as defined in claim 8 wherein said therapeutically acceptable matrix is a fibrin matrix.